Menu
Search
|

Menu

Close
X

Soligenix Inc SNGX.OQ (NASDAQ Stock Exchange Capital Market)

2.03 USD
+0.02 (+1.00%)
As of Feb 21
chart
Previous Close 2.01
Open 2.00
Volume 801
3m Avg Volume 15,427
Today’s High 2.04
Today’s Low 2.00
52 Week High 5.07
52 Week Low 1.77
Shares Outstanding (mil) 8.73
Market Capitalization (mil) 17.46
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
4
FY16
10
FY15
9
EPS (USD)
FY17
-0.897
FY16
-0.963
FY15
-3.182
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
2.99
8.67
Price to Book (MRQ)
vs sector
3.77
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
0.00
15.38
LT Debt to Equity (MRQ)
vs sector
0.00
12.01
Return on Investment (TTM)
vs sector
-200.86
13.57
Return on Equity (TTM)
vs sector
-200.86
15.19

EXECUTIVE LEADERSHIP

Christopher Schaber
Chairman of the Board, President, Chief Executive Officer, Since 2009
Salary: $412,000.00
Bonus: $115,000.00
Karen Krumeich
Chief Financial Officer, Senior Vice President, Since 2016
Salary: --
Bonus: --
Oreola Donini
Senior Vice President, Chief Scientific Officer, Since 2014
Salary: --
Bonus: --
Richard Straube
Senior Vice President and Chief Medical Officer, Since 2014
Salary: $300,000.00
Bonus: $62,000.00
Marco Brughera
Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

29 Emmons Dr Ste C10
PRINCETON   NJ   08540-5919

Phone: +1609.5388200

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

SPONSORED STORIES